The authors wish to correct a mistake on the review "The role of drug transporters in the kidney: lessons from tenofovir" regarding the details of a particular ABCC2 polymorphism \[−24C \> T (rs717620)\]. In the Section "Tenofovir and kidney transporter pharmacogenetics" on page five of the article, the second line on the second column should state the ABCC2 polymorphism as −24C \> T, rather than −24T \> C. Additionally, the sentence beginning on page five, line four of the second column should be changed from: "In a study in Japanese HIV+ patients, the *ABCC2* −24C \> T and1249G \> A polymorphisms were found to be protective for tenofovir-induced kidney toxicity (Nishijima et al., [@B1])." and instead read: "In a study in Japanese HIV+ patients, the *ABCC2* −24T \> C and 1249G \> A polymorphisms were found to be associated with the increased occurrence of tenofovir-induced kidney toxicity (Nishijima et al., [@B1])."
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